Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Ara 290 and NAD+ Interaction: Monitor | Peptide Database

Compound Profiles Ara 290 Tissue-Protective Peptide | Innate Repair Receptor Agonist Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.. NAD+ Essential Cellular Coenzyme & Anti-Aging The

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Ara 290

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects..

NAD+

Essential Cellular Coenzyme & Anti-Aging Therapy

Direct delivery to bloodstream ensures maximum cellular availability for energy production via ATP synthesis, DNA repair through PARP activation, and sirtuin-mediated longevity pathways. Supports mitochondrial function and metabolic homeostasis.

Combined Organ Load

Frequently Asked Questions

Can I take Ara 290 with NAD+?

Yes, but with caution. Both affect cellular metabolism; monitor for additive effects. Regular monitoring is advised.

Is Ara 290 and NAD+ safe together?

Based on documented research, this combination is considered monitor. No critical safety flags identified for this pair.

What are the interactions between Ara 290 and NAD+?

Both affect cellular metabolism; monitor for additive effects. This assessment has 90% confidence and is based on documented research data.

How should I time Ara 290 and NAD+?

Ara 290 has a half-life of ~20 minutes (SubQ), ~2 minutes (IV) and NAD+ has a half-life of 1-4 hours (intracellular). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Chonluten — share findings, ask questions, and learn from real experiences Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD. Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

Source: peptide-db.com ↗

Community Research

Join others researching Cartalax — share findings, ask questions, and learn from real experiences Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation. Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Subcutaneous injection is the primary administration route studied in preclinical research. Human pharmacokinetic data is very limited. Cognitive support (research protocol) 100-200mcg 1x daily SubQ

Source: peptide-db.com ↗
Side effects

Common Side Effects

Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks Initial sleep disruption or insomnia during the first week of treatment Mild nausea, particularly during the first few days Transient headache during dose initiation or titration

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →